Diuretics are a cornerstone of treatment for congestive heart failure (CHF).
Treatment for CHF typically involves diuretics to reduce fluid buildup.2 Loop diuretics specifically are often prescribed to reduce intravascular fluid volume and relieve clinical signs of volume overload.3
An innovative loop diruretic for managing CHF.
UpCard-CA1 contains torsemide, a potent loop diuretic that has a longer half-life, higher bioavailability, greater potency, and longer duration of action compared to furosemide.2
Once daily dosing.
Choosing UpCard-CA1 gives veterinarians and their clients the benefit of a once daily, easily titratable oral solution for precise and consistent dosing that can aid in owner compliance.
Curious about UpCard-CA1?
Check out our list of most frequently asked questions.
UpCard-CA1 is brought to you by Vetoquinol, the same company that brings you other innovative medications like Clevor® (ropinirole ophthalmic solution) and is backed by our Satisfaction Guarantee.
UpCard-CA1 is brought to you by Vetoquinol, the same company that brings you other innovative medications like Clevor® (ropinirole ophthalmic solution) and is backed by our Satisfaction Guarantee.
UpCard-CA1 is conditionally approved by the FDA pending a full demonstration of effectiveness under application number 141-577. It is a violation of Federal law to use this product other than as directed in the labeling.
IMPORTANT SAFETY INFORMATION: UpCard-CA1 is for use in dogs only. Do not administer to dogs with renal failure, anuria, severe dehydration, hypovolemia, or hypotension. Do not administer UpCard-CA1 concomitantly with other loop diuretics or to dogs with hypersensitivity to the active substance, torsemide, or to any of the excipients. UpCard-CA1 should be used only in stable dogs with congestive heart failure caused by MMVD which has been diagnosed by means of a comprehensive physical and cardiac examination. This drug has not been evaluated in dogs used for breeding, pregnant, or lactating bitches. The most common side effects seen in dogs with CHF due to MMVD while taking UpCard-CA1 are cough, dyspnea, pulmonary edema, and cardiac arrest. Adverse reactions not related to disease progression in dogs receiving UpCard-CA1 include polyuria and polydipsia, renal insufficiency, increased BUN and serum creatinine, urinary incontinence, hypokalemia, hypochloremia, hypercalcemia, hypomagnesemia, diarrhea, vomiting, and inappetence. For full prescribing information, visit vetoquinolusa.com/upcard-ca1-info.
References
1UpCard-CA1 Freedom of Information summary.
2Besche B, et al. Efficacy of oral torasemide in dogs with degenerative mitral valve disease and new onset congestive heart failure: The CARPODIEM study. J Vet Intern Med. 2020;34(5):1746–1758.
3Chetboul V, et al. Short-Term Efficacy and Safety of Torasemide and Furosemide in 366 Dogs with Degenerative Mitral Valve Disease: The TEST Study. J Vet Intern Med. 2017;31(6):1629–1642.
